PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all…
An institutional-grade, numbers-driven thesis on PTCT — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates PTC Therapeutics, Inc. (PTCT) 65/100 with a 12-month base-case forecast of $106.14 — +48.0% versus the current price of $71.70. PTC Therapeutics, Inc. trades at $71.70 in the Healthcare sector, with a market capitalisation of $5.98B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for PTCT is $106.14, implying +48.0% versus the current price. The model's 12-month scenario range runs from $109.92 (bear) to $124.63 (bull), with a base case of $114.22.
On the fundamentals, PTC Therapeutics shows a P/E of -146.3, trailing revenue of $1.73B, revenue growth of +114.5% YoY. This page also tracks PTCT's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
PTCT currently carries a TradersQuant composite score of 65/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $106.14 implies +48.0% from $71.70. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for PTCT is $106.14, about +48.0% versus the latest price of $71.70. Consensus is based on 26 analysts.
TradersQuant's 12-month model forecast for PTCT is a base case of $114.22, ranging from $109.92 (bear) to $124.63 (bull), an expected return of +59.3%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for PTCT over the next 12 months is $114.22 in the base case (bear $109.92, bull $124.63), versus today's price of $71.70. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for PTCT — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates PTCT's fair value at $106.14, implying +48.0% of expected upside versus the current price.
PTC Therapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
